Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation

Kleinhenz, Fabian; Pfarr, Nicole; Steinhelfer, Lisa; Lorsch, Alisa M.; Bendz, Henriette; Friedrich, Mathias; Liesenfeld, Lea; Barroux, Melissa; Maurer, Carlo; Wenzel, Patrick; Kestler, Angelika; Koppermann, Mai-Lan; Mogler, Carolin; Spahn, Stephan; Illert, Anna L.; Schmid, Roland M.; Bitzer, Michael; Lange, Sebastian

dc.contributor.author	Spahn, Stephan
dc.contributor.author	Bitzer, Michael
dc.date.accessioned	2026-03-27T09:24:22Z
dc.date.available	2026-03-27T09:24:22Z
dc.date.issued	2025
dc.identifier.issn	1083-7159
dc.identifier.uri	http://hdl.handle.net/10900/177782
dc.language.iso	en	en
dc.publisher	Oxford : Oxford Univ Press	de_DE
dc.relation.uri	http://dx.doi.org/10.1093/oncolo/oyaf322
dc.subject.ddc	610	de_DE
dc.title	Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation	de_DE
dc.type	Article	de_DE
utue.quellen.id	20251118000000_00468
utue.personen.roh	Kleinhenz, Fabian
utue.personen.roh	Pfarr, Nicole
utue.personen.roh	Steinhelfer, Lisa
utue.personen.roh	Lorsch, Alisa M.
utue.personen.roh	Bendz, Henriette
utue.personen.roh	Friedrich, Mathias
utue.personen.roh	Liesenfeld, Lea
utue.personen.roh	Barroux, Melissa
utue.personen.roh	Maurer, Carlo
utue.personen.roh	Wenzel, Patrick
utue.personen.roh	Kestler, Angelika
utue.personen.roh	Koppermann, Mai-Lan
utue.personen.roh	Mogler, Carolin
utue.personen.roh	Spahn, Stephan
utue.personen.roh	Illert, Anna L.
utue.personen.roh	Schmid, Roland M.
utue.personen.roh	Bitzer, Michael
utue.personen.roh	Lange, Sebastian
dcterms.isPartOf.ZSTitelID	Oncologist	de_DE
dcterms.isPartOf.ZS-Issue	10	de_DE
dcterms.isPartOf.ZS-Volume	30	de_DE
utue.fakultaet	04 Medizinische Fakultät